OTCM
COTXF
Oct 20, Last price
0.11USD
IPO
-10.83%
Name
Roquefort Therapeutics PLC
Chart & performance
P/E
—
P/B
—
EPS
—
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
-100.00%
Net income
-972k
L-44.29%
CFO
-784k
L-54.79%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Roquefort Therapeutics plc functions as a biotechnology firm, focusing its efforts on the discovery and development of innovative pharmaceutical treatments. The company's primary research objective is to develop therapies that target Midkine, a circulating growth factor protein and pro-inflammatory mediator, for applications in cancer treatment. Established in 2020, Roquefort Therapeutics plc has its main operations based in London, United Kingdom.
Key people
Graham Robertson
Vice President - Drug Discovery · since 2022
Sabena Sultan
Vice President - Drug Development · since 2022
Darrin Disley
Interim Managing Director, Director · since 2025
Executive Chairman of the Board · since 2021
Jean Duvall
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2022
Headquarters & legal address
85 Great Portland Street
First Floor
London W1W 7LT
GB
First Floor
London W1W 7LT
GB
Previous name
Roquefort Investments PLC
Previous name
Roquefort Therapeutics PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | ||||
Unusual Expense (Income) | ||||
NOPBT | ||||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | ||||
Net income | ||||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | ||||
BB yield | ||||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | ||||
| Cash flow | ||||
Cash from operating activities | ||||
CAPEX | ||||
Cash from investing activities | ||||
Cash from financing activities | ||||
FCF | ||||
| Balance | ||||
Cash | ||||
Long term investments | ||||
Excess cash | ||||
Stockholders' equity | ||||
Invested Capital | ||||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | ||||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | ||||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT | ||||